Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

In a cross-study analysis, omaveloxolone slowed progression in FA by at least 50% each year for 3 years compared with corresponding data from an external control group in a natural history study. 

Omaveloxolone Sustains Benefit Effect in Friedreich Ataxia at 3 Years 

Although the mortality among monitored and nonmonitored patients was similar, the monitored group had significantly more patients with severe disability and fewer with good recovery at 6 months.

Intracranial Pressure Monitoring in TBI Associated With Poorer Recovery, Raising Questions About Its Use

Videos

The professor of neurology at the Geisel School of Medicine at Dartmouth talked about recent studies presented at the International Headache Congress on a potential migraine prevention treatment targeting pituitary adenylate cyclase activating polypeptide. [WATCH TIME: 5 minutes] 

Exploring Synergistic Treatment Strategies for Migraine With Monoclonal Antibodies and Gepants: Stewart J Tepper, MD

Previous data on the 25 mg cohort of CTI-1601 showed significant reductions in frataxin levels among treated individuals with Friedreich ataxia.

FDA Clears Exploration Trial for Higher Dose of CTI-1601 for Friedreich Ataxia

The codirector of interventional neuroradiology and vice-chief of the department of neuroscience at Baptist Health Miami Neuroscience Institute provided clarity on the complexities with treating subarachnoid hemorrhage on an individual case basis. [WATCH TIME: 4 minutes]

Treatment Decision Process for Subarachnoid Hemorrhage: Guilherme Dabus, MD

The professor of neurology at NYU Langone Grossman School of Medicine discussed the Women in Neurology session she gave at IFN 2023, where women shared their experiences from their medical careers. [WATCH TIME: 3 minutes] 

Championing Women's Leadership in Neurology: Jennifer Frontera, MD

Director of the epilepsy fellowship program at NYU Langone Health; associate professor of neurology at NYU Grossman School of Medicine.

The associate professor of neurology at NYU Grossman School of Medicine discussed her talk at IFN 2023 on advancements in epilepsy treatments, highlighting new medications and surgical options. [WATCH TIME: 3 minutes] 

Recent Advances in Epilepsy Management: New Treatments and Innovative Procedures: Patricia C. Dugan, MD

Codirector of the Mount Sinai Epilepsy Program at the Icahn School of Medicine at Mount Sinai.

The codirector of the Mount Sinai Epilepsy Program at the Icahn School of Medicine at Mount Sinai talked about the Women in Neurology and Leadership session she spoke in at IFN 2023. [WATCH TIME: 3 minutes] 

Empowering Women to Develop Leadership Skills in Neurology: Lara V. Marcuse, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

Ataxia

MDS 2023

NMOSD

Narcolepsy

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

Authors

Postdoctoral researcher in the department of neurology at John Hopkins School of Medicine.

The postdoctoral researcher in the department of neurology at John Hopkins School of Medicine talked about indole-3-lactate as a signaling molecule in the gut-brain axis and its potential as a treatment for MS.  [WATCH TIME: 5 minutes]

Exploring the Impact of Indole-3-Lactate in the Gut-Brain Axis and Multiple Sclerosis: Larissa Jank, MD